Navigation Links
Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM

OXFORD, England, April 24 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures' pharmaceutical transactions experience in the healthcare and investment business sectors. The IRBM is an integrated, state-of-the-art small molecule and biological discovery centre. IRBM has an outstanding record of drug discovery including Isentress(R), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The centre has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists.

Dr Fintan Walton, CEO, PharmaVentures commented, "This research centre is a rare opportunity for a pharmaceutical company or contract research organisation to expand its operations and gain access to one of the world's foremost research centres."

A leading results driven organisation, PharmaVentures ( assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals(R) range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews and deal making trends through the world's first online pharmaceutical television channel Now in its 17th year, PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

    For further information please contact:
    Lisa Holloway

SOURCE PharmaVentures Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
2. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
6. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
7. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
8. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
9. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
10. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
11. Merck Serono Named as a Top Employer by Science Magazine
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... and SensoMotoric Instruments (SMI) announce a mobile plug and ... captured during interactive real-world tasks SensoMotoric Instruments ... of their established wearable solutions for eye tracking and ... behavior captured with SMI Eye Tracking Glasses 2w ...
Breaking Biology News(10 mins):